权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

RECOMBINANT HUMAN CC10 FOR PREVENTION OF NEONATAL BPD

用于预防新生儿 BPD 的重组人 CC10

基本信息

批准号：
2616435
负责人：
APRILE L PILON
金额：
$ 9.79万
依托单位：
CLARAGEN, INC.
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
起止时间：
1998-01-17 至 1998-07-16
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/2616435
关键词：
antiinflammatory agents bronchopulmonary dysplasia cell line drug design /synthesis /production drug screening /evaluation molecular cloning nonhuman therapy evaluation phospholipase A2 premature infant human protein purification protein structure function recombinant proteins respiratory disorder chemotherapy respiratory protein sheep ultrafiltration urine

项目摘要

A new protein therapy for the treatment and/or prevention of broncho- pulmonary dysplasia (BPD) in premature neonates is proposed. BPD is a long term inflammatory response to lung tissue damage initiated in the treatment of respiratory distress syndrome in premature infants, with surfactant and hyperbaric oxygen. The protein, called uteroglobin or CC10, is thought to be natural anti-inflammatory protein, present in the extracellular fluids of the respiratory tract. However, uteroglobin, which is normally present in the lungs of full term infants, is deficient in premature infants. CC10 has been reported to inhibit phospholipase A2's in vitro. These enzymes help initiate the inflammatory response by releasing arachidonic acid from cellular surfaces. Arachidonic acid gives rise to several inflammatory chemicals; cicosanoids, prostaglandins, and leukotrienes. The goal for Phase I is to produce about one gram of highly purified CC10, which will be tested in an animal model of neonatal respiratory distress syndrome and BPD in Phase II. PROPOSED COMMERCIAL APPLICATION The potential commercial applications for this protein include inflammatory disease conditions, including neonatal respiratory distress syndrome and broncho-pulmlonary dysplasia.

一种用于治疗和/或预防支气管炎的新的蛋白质疗法，肺发育不良（BPD）的早产儿提出。 BPD是一个肺组织损伤引发的长期炎症反应，早产儿呼吸窘迫综合征的治疗，表面活性剂和高压氧。这种蛋白质被称为子宫珠蛋白， CC 10被认为是天然的抗炎蛋白，存在于呼吸道的细胞外液。然而，子宫珠蛋白，通常存在于足月婴儿的肺部，早产儿缺乏。据报道，CC 10可抑制磷脂酶A2在体外。这些酶有助于启动通过从细胞释放花生四烯酸的炎症反应表面。花生四烯酸引起几种炎症反应，化学品;类花生酸、洋地黄素和白三烯。的目标第一阶段是生产约1克高度纯化的CC 10，在新生儿呼吸窘迫综合征的动物模型中进行测试第二阶段的BPD。建议的商业应用这种蛋白质的潜在商业应用包括炎症性疾病，包括新生儿呼吸窘迫综合征和支气管肺发育不良。